Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample.

Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample.

While molecular testing is recommended for symptomatic patients suspected of having coronavirus disease 2019 (COVID-19), limited data are available examining real-world use of tests for severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the impact of SARS-CoV-2 testing on patient outcome...

Full description

Saved in:
Bibliographic Details
Main Authors: Karen M Stockl, Jamie Tucker, Anne Beaubrun, Julia M Certa, Laura Becker, Jordan G Chase
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0313660
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1371/journal.pone.0313660

Similar Items